Collectively, our data provide compelling evidence that OSU-HDAC-44 is an HDAC targeted inhibitor and has the potential to be tested for NSCLC treatment and combination chemotherapy. This evidence concerns the gene HDAC9 and non-small cell lung carcinoma.